Healthcare Professionals

bioTheranostics discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer.

bioT3 Metastatic Cancer Solution

bioT3 is a suite of genomic-based tests that provide diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of care. The bioT3 assays deliver the right information at the right time to help patients receive the right therapy:

  • CancerTYPE ID® – Molecular classification for definitive diagnosis of tumor type and subtype
  • CancerTARGET ID – (Formerly PRÉCIS®) Actionable tumor-specific biomarkers for the selection of on-label targeted therapies
  • CancerTREATMENT ID – Next Generation Sequencing (NGS) + multi-platform biomarkers for comprehensive treatment options

Breast Cancer IndexSM

Molecular insights for breast cancer risk prognosis

Breast Cancer IndexSM (BCI) predicts breast cancer recurrence risk in patients with ER+, LN- breast cancer.4

1.) Ma, et al. Molecular Classification of Human Cancers Using a 92-Gene Real Time Quantitative Polymerase Chain Reaction Assay. Archives of Pathology and Laboratory Medicine, 130: 465-473, 2006. 2.) Erlander et al. Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification. J Mol Diag. 2011 Sept; 13(5): 493-502. 3.) Kerr SE et al. Multisite Validation Study To Determine Performance Characteristics of a 92-gene Molecular Cancer Classifier. Clin Cancer Res. 2012 May 30. 4.) Jerevall P, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011 May 24;104(11):1762-9.